As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

South Korea’s Celltrion Healthcare has begun a UK trial of its infliximab biosimilar to see if the drug can accelerate recovery from symptoms of COVID-19. The company noted that COVID-19 is ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 Company ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Celltrion Inc.'s autoimmune disease treatment, SteQeyma, has been launched in five major European nations, the Korean company ...